Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase
Brequinar analogs were evaluated through bioassays and in silico screening as species-specific inhibitors of dihydroorotate dehydrogenase (DHODH). A class of analogs known to not inhibit human DHODH dock well to Plasmodium falciparum DHODH. Therapeutic agents brequinar sodium and leflunomide (Arava™...
Saved in:
Published in | Bioorganic & medicinal chemistry letters Vol. 16; no. 6; pp. 1610 - 1615 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Elsevier Ltd
15.03.2006
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Brequinar analogs were evaluated through bioassays and in silico screening as species-specific inhibitors of dihydroorotate dehydrogenase (DHODH). A class of analogs known to not inhibit human DHODH dock well to Plasmodium falciparum DHODH.
Therapeutic agents brequinar sodium and leflunomide (Arava™) work by binding in a hydrophobic tunnel formed by a highly variable N-terminus of family 2 dihydroorotate dehydrogenase (DHODH). The X-ray crystallographic structure of an analog of brequinar bound to human DHODH was determined. In silico screening of a library of compounds suggested another subset of brequinar analogs that do not inhibit human DHODH as potentially effective inhibitors of Plasmodium falciparum DHODH. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0960-894X 1464-3405 |
DOI: | 10.1016/j.bmcl.2005.12.029 |